DXB - Research & Valuation, page-76

yeah yeah blah blah
now you’ve managed to inflate your dodgy claim to 10 years I see!!!)
id say traverea probably assumed their superior sparsentan drug would do the same, look how that turned out….
and yes, I agree 2 independent parties, both generics pushers by the looks of their websites , have indeed gone for this asset, well done. Noticeably none of the proper kidney bioPharma , the ones who have real expertise in developing and selling in nephrology , have touched this asset, which would be more convincing validation imo